LONG and HOLDING
all in -make money
Investor Business Daily
The Israeli software maker, whose customers include banks and retailers in 65 countries, focuses on protecting businesses from undetected cyber threats that get inside their network perimeter.
CyberArk scores high ratings all around, including a 98 for Earnings Per Share and Relative Strength. A 1.5 up-down volume ratio and a B+ Accumulation/Distribution Rating indicate demand for shares, as well as net buying by mutual funds.
thats why down
and gives CLDN $70 Target
In December, Marque investors Adage Capital Management and T. Rowe Price Associates invested nearly $17 million into Advaxis
Analyst Swayampakula Ramakanth of H.C. Wainwright said he believes Advaxis is in an enviable position, and that for a clinical stage company, it is well positioned for success, citing the fact that all of its product candidates are in clinical evaluations, as well as the fact that it has high profile partnerships and experienced clinical development personnel.
The firm also noted Advaxis‘s strong financial position to fund all ongoing studies to completion, after raising a total of $40 million in gross proceeds from financing in December and February. With pro forma cash of nearly $53 million, HCW said it believes the company could fund operations through fiscal year 2016.“Given the company’s strong position, we believe Advaxis is undervalued at the current market valuation of nearly $300 million,” said Ramakanth.
great technology !
Do The DD FOLKS :
Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer
PRINCETON, N.J., Aug. 25, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck, known as MSD outside the United States and Canada, throughitssubsidiaries, to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck's investigational anti PD-1 antibody, pembrolizumab.
how much do you pay per month for report? last post was erased
cybr will be climbing